GLP-1 receptor agonist therapy provides a net clinical benefit to healthy normal-weight adults aged 55-75.
- Current status
- Insufficient evidenceEvidence stable · Core question
- Why
- No randomized trial has enrolled healthy normal-weight older adults with clinical outcomes. All outcome trials required obesity/overweight, type 2 diabetes, or a specific disease (heart failure, CKD, MASH, Parkinson's, Alzheimer's). Modelling (JACC 2026) projects attenuated benefit in non-obese groups and is not evidence. Harms (gastrointestinal, gallbladder, lean-mass loss, NAION signal) are documented in the treated populations and would apply, possibly more acutely, to people without excess adiposity to lose.
- What would change it
- An adequately powered randomized trial enrolling normal-weight (BMI < 25) participants aged 55 or older.
Clinically meaningful outcomes (events, function, validated cognitive measures), not biomarkers alone.
A prespecified analysis showing benefit independent of weight change.
Follow-up of at least 2-3 years with full reporting of lean mass, bone, nutritional and gastrointestinal harms.
Independent (non-manufacturer) replication or an independent data-analysis group. - Linked studies
- 5 · 2 contradicts · 2 mixed · 1 no direct human evidence
- Last updated
- Sep 13, 2026
The status is the collection's own judgment on its assessment scale, not a GRADE certainty rating and not medical advice.
01The evidence
The evidence, sorted by what it shows
Contradicts (2)
- Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled TrialsUmbrella review · 2026 · Study tier 2 · Different population · Mixed
Umbrella review: MACE/MI benefits were driven by trials in people with established CVD; not significant without baseline CVD.
- Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART TrialRandomized trial · 2026 · Study tier 3 · Different population · Mixed · Industry funded
Lean mass fell alongside fat mass with semaglutide even in a modest-weight CKD population.
Mixed (2)
- Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trialRandomized trial · 2025 · Study tier 2 · Different population · Benefit · Industry funded
Within SELECT, benefit was consistent across baseline BMI categories (all >= 27) and largely independent of weight loss; cannot extrapolate below BMI 27.
- Mapping the effectiveness and risks of GLP-1 receptor agonistsRetrospective cohort · 2025 · Study tier 3 · Different population · Mixed
Broad benefit/harm atlas in veterans with diabetes; includes increased arthritic disorders, hypotension, pancreatitis, nephrolithiasis.
No direct human evidence (1)
- Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesRandomized trial · 2023 · Study tier 1 · Different population · Benefit · Industry funded
SELECT required BMI >= 27 and established CVD; mean BMI 33.4. Does not include normal-weight adults.
02History
How this assessment has changed
- Insufficient evidenceSep 13, 2026 · Evidence stable
initial curated status